Tafasitamab plus metronomic vinorelbine significantly inhibit phosphorylation of GSK3α/β, mTOR, p70S6K, RPS6 and TSC2 proteins in DLBCL cells. This evidence concerns the gene RPS6KB1 and diffuse large B-cell lymphoma.